Analysis on herbal medicines utilized for treatment of COVID-19

Lu Luo\textsuperscript{a}, Jingwen Jiang\textsuperscript{b}, Cheng Wang\textsuperscript{c}, Martin Fitzgerald\textsuperscript{d}, Weifeng Hu\textsuperscript{e}, Yumei Zhou\textsuperscript{f}, Hui Zhang\textsuperscript{g}, Shilin Chen\textsuperscript{a,*}

\textsuperscript{a}Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China
\textsuperscript{b}West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu 610041 China
\textsuperscript{c}Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100006, China
\textsuperscript{d}Ashdale Clinic, Cork T12 T2VK, Ireland
\textsuperscript{e}The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310000, China
\textsuperscript{f}The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou 518033, China
\textsuperscript{g}Akupunktur Akademiet, Aabyhoej 8230, Denmark

Received 30 March 2020; received in revised form 29 April 2020; accepted 9 May 2020

Abstract

As coronavirus disease 2019 (COVID-19) pandemic poses a substantial global public health threat, traditional Chinese medicine (TCM) was used in 91.50% of the COVID-19 cases in China, showing encouraging results in improving symptom management and reducing the deterioration, mortality, and recurrence rates. A total of 166 modified herbal formulae consisting of 179 single herbal medicines were collected for treating COVID-19 in China. Glycyrrhizae Radix et Rhizome, Scutellariae Radix, and Armeniacae Semen Amarum are the most frequently utilized in clinics, most of which are antipyretic (47, 26.26%), expectorant and cough-suppressing (22, 12.29%), and dampness-resolving (21, 11.73%) from traditional descriptions. A total of 1212 chemical components containing \(\beta\)-sitosterol, stigmasterol, and quercetin were primarily selected. Additionally, using complex system entropy and unsupervised hierarchical clustering, 8 core herbal combinations and 10 new formulae emerged as potentially useful candidates for COVID-19. Finally, following scaffold analysis, self-organizing mapping (SOM) and cluster analysis, 12 clusters of molecules yielded 8 pharmacophore families of structures that were further screened as pharmacological targets in human metabolic pathways for inhibiting coronavirus. This article aims to make more easily accessible and share historical herbal knowledge used in contemporary treatments in a modern manner to assist researchers contain the global spread of COVID-19.

*Corresponding author. Tel: +86 10 64032658, fax: +86 10 64013996.
E-mail address: slchen@icmm.ac.cn (Shilin Chen).

Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

https://doi.org/10.1016/j.apsb.2020.05.007

2211-3835 © 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

While COVID-19 is now being effectively controlled within China, it is increasingly affecting other countries worldwide, most notably the U.S., Iran, and Italy since Feb 25, 2020\(^1\). World Health Organization (WHO) has officially declared COVID-19 a global pandemic and announced that Europe and the U.S. have now become the epicenter of the pandemic\(^2\). Particularly, China used a unique medical guideline for disease management, which combines traditional Chinese medicine (TCM) and Western medicine together. The government of China announced that a total of 74,187 COVID-19 cases (91.50% of the total cases) were treated by combined conventional and TCM approaches with promising results in all infection stages, including significant symptom management, lower rates of deterioration and mortality, faster recovery as well as disease prevention on 23 March 2020\(^3\). Rather than conventional Western medicine, the use of TCM is mainly based on traditional knowledge and professional experience. In general, TCM can be comprehensively analyzed from several modern approaches, particularly using computational analysis of traditional herbal knowledge with modern pharmacological perspectives. This study utilized both individual herbal medicines and their respective formulae for COVID-19 in China, and proposed new formulae based on our conclusions. The authors hope that this can aid new drug exploration and clinical trial selection for the control and prevention of COVID-19 in the wider global research community.

1.1. Characteristics and experience of TCM in treating epidemic diseases

With a long history of combating epidemic diseases with relatively low mortality, TCM has accumulated a rich antiviral herb knowledgebase from clinical observation and pharmacological selection. This is historically based on a phenomenological approach and relies on complex mixtures of herbal medicines, as well as nonpharmacological holistic interventions, such as acupuncture and health lifestyle guidance\(^4\). With pandemic diseases, TCM has shown the agility to be administered more quickly and more efficiently than conventional medicine\(^4\). It asserts that health is a state of harmony between an individual’s internal physiological network of factors and that of an external environmental\(^5\). Diagnosis is through syndrome differentiation called “Bian Zheng”, a holistic analysis of clinically observed information that guides personalized treatment options\(^4,\) which may be adaptably changed dynamically during disease progression\(^\). From point of TCM, epidemic disease is considered caused by an external pathogenic attack (traditionally named pestilient Qi or evil Qi) due to climatic or environmental changes. In the battle between healthy Qi (immunity) and pathogenic Qi (pathogen), a weakened immune system results in disease, while exhaustion of healthy Qi leads to death\(^1\). Consequently, different syndromes can manifest as disease progresses. From TCM perspective, the fundamental pathogenic factor of COVID-19 would be termed as “dampness accumulation in the lung”, which invades from the exterior to the interior attacking other organs as disease develops from the early stage to mild, moderate, severe, critical, and recovery stages. According to the syndrome differentiations, the pathogenesis in the mild and moderate stages of COVID-19 is damp accumulation in the lung. During the severe and critical stages, dampness develops to “damp-heat toxin and congests in the lung”. While heat toxin “burns” or rapidly depletes Qi and Yin, this subsequently would appear as what is termed “dual vacuity of Qi and Yin of lung and spleen in the recovery stage”\(^5\). It could be otherwise expressed somewhat as exhaustion of the lung system, its moisture, membranes and resource to recover, along with its fundamental immune supporting system. Herbal formulations are then frequently modified as signs and symptoms change along with the diagnosis and corresponding syndrome differentiations. Appropriate herbal formulae are administered, containing herbs composed in a hierarchy called “Jun Chen Zuo Shi”, relating to their primary, secondary, tertiary and quaternary functional class order, respectively\(^5\). Through design, herbal formulae guide a combination of different herbal medicines based on the individual synergistic properties of each herb. The Jun (monarch) component is the principal phyto-complex targeting the major symptom of the disease. It synergizes with the Chen (minister) herbs to support its therapeutic effects. The Zuo (assistant) medicinal reduces or eliminates possible adverse or toxic effects. Lastly, the Shi (courier) herbs facilitate the delivery of the principal components to desired sites (e.g., target organ), or facilitate the overall action of the other components. The whole formula thus strive for a synergistic effect that targets active phytochemicals to their designated sites of action\(^6\). Furthermore, herbs can be administered through a diverse number of routes including oral intake, nasal inhalation, moxibustion, and herbal plasters (Fig. 1).

TCM posits that epidemic diseases occur as a result of macrorclimate or physical changes, leading to the Yin—Yang imbalance of the body followed by the development of a variety of syndromes. Herbal formulae are then organized based on “Jun Chen Zuo Shi” compatibility in accordance with traditional syndrome differentiations, such as “the eight principles”. In contrast, conventional medicine initially categorizes the microorganisms into virus, bacteria, mycoplasma, parasite, etc. The corresponding anti-microorganism drugs are then given in combination with vaccines and immunomodulators.

China historically has a high national epidemic occurrence frequency, sometimes as much as 25% \textit{per annum} during the 770 B.C. to 1911 A.D. period\(^7\). At least 365 major documented plague outbreaks throughout Chinese history (from 674 B.C. to 1911 A.D.) have been identified. Two particular spikes, documented outbreaks which occurred during the Han dynasty to the Three Kingdoms period (25—255 A.D) and again from the end of the Ming dynasty to the beginning of the Qing dynasty (1622—1656 A.D.)\(^8\). Hundreds of years of treating epidemics, TCM epidemiology development has enriched and rapidly advanced. These resultant TCM theories have contributed to a notable decrease in mortality during those times\(^9\). A large number of empirical prevention strategies thus developed due to the practical necessities for fighting plague, including advances in the development of preventative herbal formulations, aromatic herb
Figure 1  Comparison between traditional Chinese medicine (TCM) and conventional medicine conceptual bases for treating epidemic disease.
applications, fumigation, quarantine and disinfection (556—559 A.D.)\textsuperscript{24}, vaccination (1695 A.D.)\textsuperscript{5,16}, hygiene, and sanitation maintenance, etc\textsuperscript{7—19}. More recently, China practiced combining Western and Chinese medicines, which have significantly reduced mortality rates in outbreaks of encephalitis B (1955—1957)\textsuperscript{20—23}, and severe acute respiratory syndrome (SARS) in 2003\textsuperscript{24,25}. The rich experience and herbal knowledgebase in fighting pandemics, are now explored here as a foundation to further explore potential effective components and combinations in herbal medicines using more recent advances in data analysis.

2. Materials and methods

The National Health Commission of China has so far published seven editions of clinical guidelines of Recommended Approaches for COVID-19 Diagnoses and Treatments\textsuperscript{26} (the fifth edition was applied in this study), while 24 provinces and Wuhan city have also published their recommended protocols for COVID-19, all of which recommended the application of TCM herbal formulae. Here, 166 modified herbal formulae including 99 classical prescriptions and herbal patents were collected from these sources (Supporting Information Table S1). A dataset of 99 classical prescriptions and herbal patents were collected from these sources (Supporting Information Table S1). A dataset of standardized names was then compiled, by substituting all of the polysemes, synonyms and acronyms of the herbs according to Chinese Pharmacopoeia (2015 edition)\textsuperscript{27} and Chinese Materia Medica\textsuperscript{28}. The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform\textsuperscript{29} (http://tcmspw.com/tcmsp.php) was then utilized for searching the chemical components of 179 single herbs. Only components with oral bioavailability (OB) > 30% and drug-likeness (DL) > 0.18 were included. The frequency of occurrence of herbal formulae and single herbs were calculated, in addition to the frequency of therapeutic effects, categories of medicinal properties, and chemical components.

The core combinations of herbs and new prescriptions were analyzed using modified mutual information\textsuperscript{30} and unsupervised hierarchical clustering techniques\textsuperscript{31}. Additionally, scaffold analysis, self-organizing mapping (SOM), and cluster analysis [run by custom reconfigured, Datawarrior, in a JAVA runtime framework within a Mac OS Catalina v.10.15.3 (19D76) environment] were employed to classify diverse herbal medicines into families of structures which are distinctly dissimilar for further evaluation as candidates in preventing and treating COVID-19. The 1212 chemical components were converted to Murcko scaffolds, dissecting molecules into ring systems, linkers, side chain atoms, and frameworks, by scaffold analysis\textsuperscript{32}. SOM arranges the position of these structures in two-dimensional space, after which the dataset contains inherently similar structures and is suitable for inclusion and further cluster analysis\textsuperscript{33}. Finally, the cluster map of the complete dataset was computer generated followed by visually assessing the largest common groupings of clusters, by reducing the cluster numbers manually until all the disparate clusters without neighbors were included, but the main clusters remained\textsuperscript{34}.

Figures were plotted using OriginPro 2018C (64-bit) SR1b 9.5.1.195 (One Roundhouse Plaza OriginLab Co., Northampton, MA, USA), R language [no IDE (integrated development environment), R from the Linux terminal R version 3.5.1 (2018-007-02, “Feather Spray”\textsuperscript{35}), the R function for Statistic Computing Platform: x86_64-pc-Linux-gnu (64-bit)]\textsuperscript{36} and Pajek visualization\textsuperscript{37}.

3. Results

3.1. Statistical analysis of herbs and formulae for treating COVID-19 in China

3.1.1. Frequently utilized formulae and individual herbs for treating COVID-19

The top 10 most frequently utilized herbal formulae were: An Gong Niu Huang pill, modification of Ephedra and Apricot Kernel decoction (Ma Huang Xing Ren Gan Cao Shi Gao Tang), gypsum and licorice Xuan Bai Cheng Qi decoction, Yin Qiao powder, Zi Xue powder, Xue Bi Jing decoction, Hou Po Xia Ling decoction, Lian Hua Qing Wen decoction, Hou Pu Xia Ling decoction, upbearing and downbearing powder (Sheng Jiang San), and Su He Xiang pill (Supporting Information Table S2). The standardized herb name list consists of 179 herbs (Supporting Information Table S3.1). In total, 99 classical herbal formulae were represented 423 times, and 179 single herbs represented 2760 times. The top 10 most frequently utilized herbs in 166 herbal formulae were Glycyrrhizae Radix et Rhizome (Gan Cao, 139, 83.73%), Scutellariae Radix (Huang Qin, 101, 60.84%), Armeniacae Semen Amarum (Ku Xing Ren, 87, 52.41%), Lonicerae Japonicae Flos (Jin Yin Hua, 82, 49.40%), Forsythiae Fructus (Lian Qiao, 81, 48.80%), Ephedrae Herba (Ma Huang, 74, 44.58%), Poria (Fu Ling, 65, 39.16%), Pogostemon Cablin (Guan Huang Xiang, 63, 37.95%), Citri Reticulatae Pericarpium (Chen Pi, 57, 34.34%), and Platycodonis Radix (Jie Geng, 55, 33.13%, Fig. 2 and Table S3.1). Glycyrrhizae Radix et Rhizoma (Gan Cao) was most frequently utilized in observational, mild, moderate, severe, and critical stages. Scutellariae Radix (Huang Qin) and Armeniacae Semen Amarum (Ku Xing Ren) were most frequently applied in moderate and severe stages, while Scutellariae Radix was also mostly utilized in critical stage and Armeniacae Semen Amarum in mild stage. Other frequently utilized in each clinic stage include Lonicerae Japonicae Flos (Jin Yin Hua, observational stage), Astragali Radix (Huang Qi, observational stage), Gardeniae Fructus (Zhi Zi, critical stage), Platycodonis Radix (Jie Geng, mild stage), Aconiti Lateralis Radix Praeparata (Fu Zi, critical stage), Poria (Fu Ling, recovery and severe stages), and Ophiopogonis Radix (Ma Dong, severe stage). The most frequently applied herbs are antipyretic (47, 26.26%), expectorant and cough-suppressing (22, 12.29%), and dampness-resolving (21, 11.73%) in nature (Fig. 2 and Table S3.2), while the medicinal parts of the most frequently applied herbs are Radix and Rhizome (83, 46.37%), Fructus and Semen (42, 23.46%), and Herba and others (28, 15.64%, Fig. 2 and Tables S3.3 and S3.4). As 23 herbal medicines without fully defined chemical components were excluded, a total of 1212 chemical components with OB>30% and DL > 0.18 were collected from the remaining 156 herbs. The most frequently used chemical components possibly related to the antiviral signing pathway are β-sitosterol (1194), stigmasterol (1195), and quercetin (945, Fig. 2 and Supporting Information Fig. S1). Categorizing a total of 1212 components into 16 groups by traditional therapeutic effects, 591 components belong to the heat-clearing class, 312 belong to expectorant and cough-suppressing, and 243 belong to exterior-relieving class (Fig. 2 and Fig. S1).

Fig. 3 elucidates the potential therapeutic effects of the 10 most frequently utilized herbal ingredients and their pharmacological activities. These herbal components could provide guidance for future drug discovery to combat COVID-19. Glycyrrhizae Radix et Rhizome (Gan Cao) has long been considered the “excellent
“reconciler” to assist herb synergy while itself can nourish Qi, alleviate pain, eliminate phlegm and relieve cough. It contains over 20 kinds of triterpenoids and 300 types of flavonoids. It was reported that its active compounds possess antiviral, antimicrobial, anti-inflammatory, and immunomodulatory activities that contribute to neuro-regenerative and protective, alimentary, respiratory, endocrine and cardiovascular systems. Several reports showed that glycyrrhizin, 18β-glycyrrhetinic acid, and other flavonoids isolated from Glycyrrhizae Radix et Rhizome (Gan Cao) possess anti-inflammatory activity. Its extracts support beneficial effects in acute and chronic inflammatory conditions and significant antiviral activities against human immunodeficiency virus (HIV), SARS-CoV, herpes simplex virus (HSV), influenza virus (IAV-H3N2), rotavirus, enterovirus, coxsackievirus, varicella zoster virus, and respiratory syncytial virus. It was accepted that glycyrrhizin and 18β-glycyrrhetinic acid suppress proinflammatory cytokine cyclooxygenase-2 (COX-2), myeloperoxidase, iNOS, TNF-α, NF-kB, HMGP 1, PGE 2, DPPH radicals, IL-6, IL-10, and TGF-β, as well as activation of ABCA1. In vitro studies have shown that glycyrrhizin inhibits influenza virus by decreasing HMGB1 binding and restraining interactions between host proteins and viral macromolecules. H5N1 by controlling H5N1-induced proinflammatory gene expression. Additionally, glycyrrhizin, 18β-glycyrrhetinic acid, and licochalcone A also presented immunomodulatory activity. Glycyrrhizin revealed a fine immune stimulant and antiviral effect against duck hepatitis virus (DHV). A combination of glutamyl-tryptophan and glycyrrhizin exerts a protective effect in reducing the death of H3N2 IAV-infected mice. In vivo and clinical studies have shown that these compounds protect mice against disseminated candidiasis, and relieved experimental autoimmune encephalomyelitis in mice, increased the endpoint serum antibody titers, and performed as an immune stimulant against DHV. All these reports affirmed the immunomodulatory activity of Glycyrrhizae Radix et Rhizome (Gan Cao) and indicated that it might be a candidate for novel immunomodulatory medicine development.

Scutellariae Radix (Huang Qin) possesses broad therapeutic effects including antipyretic and hemostatic effect, moistening dryness, and detoxifying toxicosis. Flavonoids are the most abundant constituents, pharmacologically active with great potential in treating inflammation, cancer and virus-related diseases. Its anti-inflammatory and anti-oxidative effects are possibly related to cytokine inhibition, nitric oxide (NO),
Figure 3  Top 10 most frequently applied herbs with therapeutic effects and chief chemical components possessing well-defined pharmacological activities. Only the chief chemical components with relatively well-elucidated pharmacological activities are shown. Chemical structures were downloaded from the National Center for Biotechnology Information. Glycyrrhiza Radix et Rhizome (Gan Cao): glycyrrhetinic acid (C_{30}H_{46}O_{4}, MW = 470.7); Scutellariae Radix (Huang Qin): baicalein (C_{15}H_{10}O_{5}, MW = 270.24); Armeniacae Semen Amarum (Ku Xing Ren): amygdalin (C_{20}H_{27}NO_{11}, MW = 457.48); Lonicerae Japonicae Flos (Jin Yin Hua): chlorogenic acid (C_{16}H_{18}O_{9}, MW = 354.31); Forsythiae Fructus (Lian Qiao): forsythiaside (C_{29}H_{36}O_{15}, MW = 624.65); Ephedrae Herba (Ma Huang): ephedrine (C_{10}H_{15}NO, MW = 165.23); Poria (Fu Ling): pachymic acid (C_{33}H_{52}O_{5}, MW = 528.85); Pogostemon Cablin (Guang Huo Xiang): patchouli alcohol (C_{15}H_{26}O, MW = 222.37); Citri Reticulatae Pericarpium (Chen Pi): hesperidin (C_{28}H_{34}O_{15}, MW = 610.62); Platycodonis Radix (Jie Geng): platycodin D (C_{57}H_{92}O_{28}, MW = 225.49, Supporting Information Table S9).
chemokine, and growth factor production in macrophages\textsuperscript{65–67}, as confirmed by in vitro and in vivo studies\textsuperscript{68,69}. Furthermore, Scutellariae Radix (Huang Qin) can inhibit the replication of the influenza virus in mice\textsuperscript{70}. Baicalin demonstrated its anti-inflammatory effect by inhibiting the binding of chemokines to human leukocytes and cells transfected to express specific chemokine receptors\textsuperscript{71}. Its mechanism was studied on COX-2 gene expression in LPS-induced Raw 264.7 cells, and it might inhibit the binding activity of C/EBPβ DNA\textsuperscript{72}. Baicalin can also inhibit human immunodeficiency virus type 1\textsuperscript{73,74}, and block DNA synthesis of human cytomegalovirus\textsuperscript{75,76}.

Armeniacae Semen Amarum (Ku Xing Ren) has been used for the treatment of pain and inflammatory diseases such as asthma, bronchitis, emphysema, constipation, nausea, leprosy and leukoderma\textsuperscript{77}. The herb has been used to reduce fever, relieve cough and quench thirst. Amygdalin is the major compound, which has been reported to have anti-inflammatory and analgesic effects in the inhibition of the COX-2 pathway\textsuperscript{78}. Ephedrae Herba (Ma Huang) has traditionally been used for coughs, colds, bronchial asthma, flu, fever, edema, and arthralgias. Ephedrine is the major isomer comprising 30%–90% of the total alkaloids\textsuperscript{79}. It enhances the release of norepinephrine from sympathetic neurons. The vasoconstrictor and bronchodilator effects explain the traditional use of Ephedrae as a nasal decongestant and anti-asthmatic\textsuperscript{80}. It was reported that the growth of H1N1 virus was inhibited when the cells were treated with its extract immediately after infection. Its inhibitory effect was completely or partially reversed by FeCl3, a tannin-reactive agent, suggesting that tannin is one of the active components in the extract\textsuperscript{81}.

Citri Reticulatae Pericarpium (Chen Pi) promotes the circulation of “Qi” and is widely taken for coughing by drying dampness and expectorating phlegm\textsuperscript{82}. Its main components are volatile oils, flavonoids, and alkaloids, possessing wide pharmacological and beneficial effects on the digestive and respiratory systems. Research has shown it having antitumor, antioxidant and anti-inflammatory properties\textsuperscript{79}. Its anti-inflammatory effects are mediated by reducing the secretion of proinflammatory cytokines including NO, TNF-α, IL-1β, and IL-6\textsuperscript{80,81}. Hesperidin has been shown to inhibit inflammatory cell infiltration. The co-administration of hesperidin and naringenin can ameliorate airway structural remodeling and relieving pulmonary symptoms\textsuperscript{82}. It was found that extracts from Glycyrrhizae Radix et Rhizome (Gan Cao), Forsythiae Fructus (Lian Qiao), and Andrographis Paniculata (Chuan Xin Lian) suppressed influenza A virus-induced rantes secretion in human bronchial epithelial cells. It was thereby suggested that these herbs could be effective for chronic inflammatory disorders caused by viral infection\textsuperscript{82} (Fig. 3 and Supporting Information Tables S5.1 and S5.2).

3.1.2. Core combination of herbs and chemical components by cluster analysis

We have explored 8 groups of core combinations by hierarchical clustering with 98 individual herbs whose modified mutual information is over 0.03, drawn from the 166 collected formulae for COVID-19. The first group consists of Fritillariae Cirrhosae Bulbus (Chuan Bei Mu) which are antiinflammatory, Q1-reinforcing Ginseng Radix et Rhizome (Ren Shen), antipyretic and detoxifying Scutellariae Radix (Huang Qin), and other 10 herbs. The second group includes antipyretic and detoxifying Moutan Cortex (Mu Dan Pi), blood- and liver-nourishing analgesic Paeoniae Radix Alba (Bai Shao), Qi and Yin nourishing and antipyretic Panacis Quinquefofills Radix (Xi Yang Shen). The third core combination contains Citri Reticulateae Pericarpium (Chen Pi), which can strengthen the spleen, harmonize the stomach, move Qi and clear phlegm, Pogostemon Cablin (Guang Huo Xiang) which can harmonize the spleen and stomach, and Portia (Fu Ling) which can strengthen the spleen, dissolve dampness, and calm the mind. The fourth group consists of blood-activating Angelicae Sinensis Radix (Dang Gui), Carthamus Tintorius (Hong Hua), and Chuanxiong Rhizome (Chuan Xiong), blood-regulating Ginseng Radix et Rhizoma Rubra (Hong Shen), blood-cooling and heat-clearing Paeoniae Radix Rubra (Chi Shao), and blood-cooling and stasis-removing Salviae Miltiorrhizae Radix et Rhizome (Dan Shen). The fifth group is made of antitussive antiasthmatics Armeniacae Semen Amarum (Ku Xing Ren), antipyretic and detoxifying Forsythiae Fructus (Lian Qiao), and diuretic and exterior-releasing Ephedrae Herba (Ma Huang). The sixth group focuses on expelling the pathogen and strengthening the spleen. The seventh group aims at tonifying Qi and nourishing Yin. The last one regulates Qi, warms the interior, and relieves pain (Fig. 4A and Supporting Information Table S6.1). The core combinations found here correspond with the traditional rules of herbal medicine composition and compatibility to reinforce particular functions in the treatment of COVID-19. For core combinations of chemical components, only herbs appeared twice or above and with modified mutual information over 0.1 were included, at last 12 core combinations were obtained. Some chemical components share the same category of traditional therapeutic effect (Fig. 2D), which may signify potential synergistic effects. There are mutual groupings within these core combinations of herbal pairs and chemical components, thus supporting that the herbs and formulae containing these properties may act as potential candidates for COVID-19 treatment (Fig. 4B and Table S6.2).

3.1.3. Clusters of structures and active pharmacophores yielded by scaffold and cluster analyses

1164 Murcko scaffolds and 40 aliphatic straight chain fragments were removed from the data and not considered further as they produced useless ring structures (Fig. 5A). SOM resulted in distinctly dispersed map of structural similarly components. Therefore, the dataset is diverse yet contains inherently similar structures suitable for inclusion and further cluster analysis. The clusters were self-organized (SOM) based on the ring system (Fig. 5B). Analysis mapping of the nearest neighbours visually exhibited both diverse clusters and clearly associated families of structures (Fig. 5C). Finally, 12 significant clusters with distinctly different structures were discovered, from which one representing each family were screened in silico for coronavirus activity, against approximately two million molecules using ChEMBL online database\textsuperscript{82} and their associated pharmacological targets in human metabolic pathways. Eight active pharmacophores were yielded (Fig. 5D and E, and Supporting Information Table S8 and S9) and further scaffold analysis of which yielded a total of 1103 similar-type molecules. Further metabolic targeting of these in silico resulted in 575 (52%) possessing antiviral activity against coronaviruses: corona generally (2%), feline corona (19%), human corona (4%) and SARS (74%), possessing published antiviral assay properties of: inhibition (31%), IC\textsubscript{50} (31%), and EC\textsubscript{50} (30%). Positive results specifically in the human corona category were for: human coronaviruses, OC43 (12%), 229 E (16%) and NL63 (72%). Herbs containing the same pharmacophore clusters above, due to their chemical scaffold similarity and nearest neighbours, are more likely to behave pharmacologically.
similar. Therapeutically they may possess synergistic properties when used in combinations due to possessing chemical similarities, yet different when act on similar metabolic targets in slightly a different manner. This is the inverse analog of “shotgun chemistry” where similar compounds are applied en masse, often indiscriminately in either chemical, biological, DNA analysis or in drug discovery. Further pharmacophore synergy investigations are encouraged and could be thought of “selective shotgun” chemistry based on these findings.

3.1.4. Ten new formulae developed by unsupervised hierarchical clustering

A total of 10 new prescriptions were developed through the unsupervised hierarchical clustering technique from the 166 herbal formulae for COVID-19. The first formula targets (from a TCM perspective) regulating Qi, relieving cough and shortness of breath. One difference in this formula from the others is the inclusion of warm and Qi-tonic herbs, Ginseng Radix et Rhizome (Ren Shen) and Aconiti Lateralis Radix Praeparata (Fu Zi), supporting that this formula can strengthen the healthy Qi and expel pathogenic factors simultaneously. According to the compatibility rules of herbal formulae, Armeniacae Semen Amarum (Ku Xing Ren) and Asteris Radix et Rhizome (Zi Wan) function as the Jun (monarch) to relieve asthma and expel the phlegm; Belamcandae Rhizoma (She Gan) and Chrysanthemi Flos (Ju Hua) function as Chen (minister) to clear the heat and remove the toxin; assisted by Cori Fructus (Shan Zhu Yu) and Dioscoreae Rhizoma (Shan Yao) to strengthen the kidney and spleen; and, Ephedrae Herba (Ma Huang) function as Shi (courier) disperse lung Qi. The second formula mostly consists of diuretic dampness-resolving herbs. Alismatis Rhizoma (Ze Xie) and Polyborus (Zhu Ling) work as Jun to remove dampness; with Tetrapanacis Medulia (Tong Cao) and Coicis Semen (Yi Yi Ren) as Chen to support the diuretic effect of Jun herbs; Amomi Fructus Rotundus (Dou Kou) and Sojae Semen Praeparatum (Dan Dou Chi) as Zuo to dissolve the exterior and dampness; and Curcumae Longae Rhizoma (Jiang Huang) as Shi to regulate Qi and activate blood. The third formula focuses on relieving cough and expelling phlegm. Amomi Fructus (Sha Ren) and Descurainiae Semen Lepidii Semen (Ting Li Zi) are the Jun hers, regulating Qi and relieving asthma; with Lablab Semen Album (Bai Bian Dou) as Chen herb to harmonize spleen and stomach; Trichosanthis Fructus (Gua Lou) and Persicae Semen (Tao Ren) as Zuo herb to expel sputum and remove stasis; and Rhei Radix et rhizoma (Da Huang) as Shi herb to clear heat and remove toxins. The fourth is a modification of classic formula Su He Xiang pill, which mainly consists of aromatic herbs to regulate Qi and relieve pain. Liquidambar (Su He Xiang) and Benzoium (An Xi Xiang) act as Jun herbs to aid recovery of the mind, dispel cold and relieve pain; Aucklandiae Radix (Mu Xiang) and Caryophylli Flos (Ding Xiang) as Chen herbs to regulate Qi and activate blood; assisted by Piperis Longi Fructus (Bi Ba) and Atractylodis Macrocephalae Rhizoma (Bai Zhu) to strengthen spleen and expel cold; with astringent Chebulae Fructus (He Zi) as Shi herb to balance the formula by preventing excess dispersing. The fifth is a modification of the classic formula Huo Xiang Zheng Qi powder, which releases the exterior and dissolves dampness. Herba Agastaches (Huo Xiang) is an anti-perspirant herb, acting as the Jun to dissolve the exterior and expel wind cold; Perillae Folium (Zi Su Ye) and Angelicae Dahuricae Radix (Bai Zhi) act as Chen herbs to strengthen the effect of expelling wind cold, and to regulate Qi and activate blood; Zuo herbs Magnoliales Officinalis Cortex (Hou Po) and Citri Reticulatae Pericarpium (Chen Pi) can regulate Qi, strengthen spleen, and dissolve phlegm; with Poria (Pu Ling) as Shi herb to help dissolving dampness. The sixth is a modification of classic formula Ren Shen Bai Du powder, which releases the exterior and clears internal heat with antipyretic herbs. The antipyretic Jun hers Puerariae Lobatae Radix (Ge Gen) and Bupleuri Radix (Chai Hu) work together to release the exterior; Chen herbs Aurantii Fructus (Zhi Qiao) and Peucedani Radix (Qian Hu) are together to clear heat, expel wind, and dissolve phlegm; Zuo herbs Angelicae Sinensis Radix (Dang Gui) and Chuanxiong Rhizoma (Chuan Xiong) can regulate and activate blood, with Shi herb Platycodonis Radix (Jie Geng) to reinforce the effect of expelling phlegm. The seventh is a modification of classic formula Yin Qiao powder, which emphasizes on clearing heat and releasing the exterior. Jun herb Forsythiae Fructus (Lian Qiao) can release the exterior, clear heat and remove toxin; Chen herbs Lophatheri Fructus (Zhi Qiao) and Phragmites Radix (Qian Hu) are together to clear heat, expel wind, and dissolve phlegm; Zuo herbs Angelicae Autismi Radix (Dang Gui) and Chuanxiong Radix (Chuan Xiong) can regulate and activate blood, with Shi herb Platycodonis Radix (Jie Geng) to reinforce the effect of expelling phlegm. The eighth formula regulates Qi, releases the exterior and removes dampness. Jun herb Atractylodis Rhizoma (Cang Zhu) can strengthen spleen to dissolve dampness, Chen herbs Tsaooko
Fructus (Cao Guo) and Notopterygii Rhizoma et Radix (Qiang Huo) can expel wind damp, regulate Qi, and dispel pathogenic factors; assisted by Arecae Semen (Bing Lang) and Lonicerae Japonicae Flos (Jin Yin Hua) to clear heat toxin and remove dampness; Shi herb Zingiberis Rhizoma Recens (Sheng Jiang) can reinforce spleen, activate blood, and expel cold. The ninth formula nourishes Yin and Qi, reinforces the lung and relieves cough. Jun herbs Panacis Quinquefolii Radix (Xi Yang Shen) and Glehniae Radix (Bei Sha Shen) nourish the Qi and Yin of lung; with Chen herbs Schisandrae Chinensis Fructus (Wu Wei Zi) to nourish Yin and protect the liver and Houttuyniae Herba (Yu Xing Cao) to clear heat toxin of lung; assisted by Cyrtomium Fortune (Guan Zhong) to reinforce the effect of heat toxin removing and diaphoretic herb Cinnamomi Ramulus (Gui Zhi) to release the exterior; Shi herb Jujubae Fructus (Da Zao) reinforces Qi and nourishes blood. The last one is a modification of classic formula Yu Pin Feng powder, which can enhance the Qi and consolidate the exterior. Jun herb Astragali Radix (Huang Qi) consolidates the exterior and reinforces Qi; Chen herb Atractylodis Macrocephalae Rhizoma (Bai Zhu) strengthens spleen and dissolves dampness, Zuo herb Saposhnikoviae Radix (Fang Feng) expels wind and releases the exterior; with Shi herb Pseudostellariae Radix (Tai Zi Shen) to nourish Yin and help strengthen Qi. The 10 formulae developed here may serve as a reference for herbal clinical applications or be used for COVID-19 prevention (Fig. 6 and Table S7).

4. Discussion

TCM asserts that pandemic diseases occur naturally and periodically as the climate or geographic situations change. TCM also emphasizes the enhancement of immune function to encourage the body to expel external pathogens. This is also done through the use of herbal formulations derived from careful analysis of syndromes likely to arise in a given year or season. This preventative strategy has also been useful in the treatment of COVID-19. In addition to assisting in the relief of symptoms for most patients in all stages, this approach is especially appealing due to the strong emphasis on both prevention and participation in the recovery of various disorders. The prevention strategy appears in three parts: preventing occurrence, deterioration, and reoccurrence. TCM seems to have shown encouraging results in reducing the rate of mild illness, deterioration to severe stage and overall...
mortality as well as shortening total disease duration. When combined with modern biomedicine, herbal medicines could relieve hypoxemia and chronic obstructive pulmonary disease (COPD)\textsuperscript{84}, exert antiviral, anti-inflammatory, and immunoregulatory activities.

The therapeutic effects of TCM in treating COVID-19 have recently been explored by initial clinical trials. It was reported that 139 clinical trials including 47 programs (33.8\%) involving TCM interventions have been registered either on Chinese Clinical Trial Registry (www.chictr.org.cn) or the American Clinical Trial Registry (ClinicalTrials.gov)\textsuperscript{85–87}. An initial randomized controlled trial (RCT) with a total of 52 cases was conducted in a Wuhan hospital at the epicenter of the outbreak. The TCM treatment group (34 cases) showed positive results in symptom relief, reduction of body temperature, length of the average hospital stay in reductions of incidences of middle stage transforming to the severe stage and increased recovery rates, yet a larger number of cases needs to further justify the results\textsuperscript{87}. It was reported that 33 out of 86 COVID-19 cases (including 65 severe cases and 31 critical cases) were cured with integrative treatments by relieving symptoms and preventing the deterioration to severe stage\textsuperscript{88}. The Chinese herbal formula Lian Hua Qing Wen decoction significantly improved symptoms of fever, cough, fatigue and shortness of breath\textsuperscript{89}. Further evidence-based studies are needed to prove the therapeutic effects of TCM in defeating COVID-19.

TCM is a combination of abundant co-occurring bioactive compounds, an invaluable source of therapeutic agents used over a relatively long period in history\textsuperscript{90}. Medicinal compatibility models can now reduce the number of targets for the identification of active ingredients, which makes the arbitrary nature of the drug discovery process more efficient and effective\textsuperscript{7}. Plant-based medicines remain the most principle source of therapeutics for much of the world’s population, and plant-derived products remain important sources for much of the world’s population. The development of artemisinin-based antimalarials represents one of the great recent achievements for ethnomedicine\textsuperscript{91}. Many initial RCTs have been conducted proving the effects of herbal formulae for treating infectious diseases with encouraging results\textsuperscript{92}. In 2011, a clinical trial was conducted comparing the effects between oseltamivir and Ma Xing Shi Gan-Yin Qiao San decoction for H1N1, which suggested that Ma Xing Shi Gan-Yin Qiao San could be used as an alternative treatment of H1N1 influenza virus infection\textsuperscript{93}.

This study relies on computational analysis, which has the inherent weakness of not possessing aspects of qualitative judgment and “common sense”, that human conducted analysis possesses. To offset this as much as practically possible, this study’s scope only focused on herbal medicines which have been developed, selected and proficiently used in practice over thousands of years. Additionally, it included herbs only which have been well studied, possessing “drug like” bioavailability, further bringing a “real-world”, pharmacological information to the initial dataset. The application of relatively novel computational, pattern recognition and \textit{in silico} methodologies to a preselected knowledge base of herbal formulae most frequently used, in-part attempts to overcome the shortcomings of the network analysis and computational analysis approach. The 8 resulting pharmacophores and core combinations were based on firstly traditional use, secondly “drug like” characteristics and thirdly reported \textit{in silico} pharmacophore structure. Therefore, we propose they present the most likely candidates, taking the constraints of this study into account, to be included, in few multiples or in combination to support the composition of completely novel COVID-19 herbal formulae. The strengths of computational methods far outweigh their weaknesses. They bestow the ability to recognize and extrapolate useful patterns from herbal datasets which would otherwise take many years, if at all possible for human researchers to explore and uncover. The combination of this blended approach, as presented here, utilizes the combined advantages of both, to enable new useful knowledge obtained from a meaningful practical foundation.

The pharmacologically active ingredients of a phyto-complex are not always the original molecules in its natural state, but maybe their host-specific metabolites or molecular complexes formed following co-administration with other herbs. The multicomponent nature of traditional medicines leads to multiple potential molecular interactions, multiple targets, and a myriad of metabolic byproducts, which requires a more network-oriented and holistic approach\textsuperscript{84}. The approach could be further refined by the application of omics technologies to optimize the synergistic effect of herbal remedies. With clinicians and basic researchers creating a database of personal
therapeutic responses, continual improvements to the evolution and creation of herbal formulations would become possible. Integration of Western and Chinese medical conceptual perspectives has enormous potential for constructing modern technological and social innovations. They are poised to merge within the arena of personalized medicine systems, wherein patients can take a greater role in managing their health and wellness. In a time of increased international awareness of the environment, health and personal responsibility for mankind, an integration of East and West should most likely be mutually beneficial. As the global spread of COVID-19 continues to worsen, it is necessary to disseminate the many advantages of traditional medicines for the prevention and treatment of COVID-19. Bridging the gap between traditional and conventional medicine during this global COVID-19 spread is both timely and crucial. We sincerely hope that this study will serve as a reference to the global COVID-19 research community.

Acknowledgements

The authors thank Dr. Zheng Yu, Dr. Jialie Sun, Dr. Changhe Yu, Dr. Jason D. Robertson, Dr. Jonathan Chang, Dr. Lei Fan, Dr. Xu Zhang, Jiaxing Liu, and Xin Xiong for their contributions to this article.

Author contributions

Shilin Chen conceived the study. Weifeng Hu, Yumei Zhou, and Lu Luo collected the COVID-19 protocols and standardized the lists. Weifeng Hu, Jingwen Jiang, Martin Fitzgerald and Lu Luo analyzed the data. Jingwen Jiang, Cheng Wang, Martin Fitzgerald, Hui Zhang, and Lu Luo plotted the figures. Shilin Chen and Lu Luo drafted the first version of the manuscript, and all authors proofread the final text.

Conflicts of interests

All authors declare no conflict of interests.

Appendix A. Supporting information

Supporting data to this article can be found online at https://doi.org/10.1016/j.apsb.2020.05.007.

References

1. WHO. Coronavirus disease (COVID-2019) situation report-36. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200225-sitrep-36-covid-19.pdf?sfvrsn=2791b4e0_2; 25 Feb 2020. Geneva, Switzerland.

2. Ryan J. WHO declares coronavirus outbreak a pandemic. USA: CNET; 11 March 2020. Available from: https://www.cnet.com/news/who-declares-coronavirus-outbreak-a-pandemic/.

3. CNR News. National Administration of Traditional Chinese Medicine: the total effective rate of traditional Chinese medicine is over 90%. Available from: https://baijiahao.baidu.com/s?id=1661948682025096958&wfr=spider&for=pc; 23 Mar 2020.

4. He W, Han H, Wang W, Gao B. Anti-influenza virus effect of aqueous extracts from dandelion. Virol J 2011;8:538.

5. Witt CM, Liu J, Robinson N. Combining omics and comparative effectiveness research: evidence-based clinical research decision-making for Chinese medicine. Science 2015;346:S10–2.

6. Leung E, Wong V, Jiang Z, Li T, Liu L. Integrated network-based medicine: the role of traditional Chinese medicine in developing a new generation of medicine. Science 2014;346:S16–9.

7. Wang Y, Xu A, Zheng. A systems biology approach to diagnosis and treatments. Science 2014;346:S13–5.

8. Zhao X, Zheng X, Fan TP, Li Z, Zhang Y, Zheng J. A novel drug discovery strategy inspired by traditional medicine philosophies. Science 2015;347:S38–40.

9. Gong S. Changes of the temporal-spatial distribution of epidemic disasters in 770 B.C.–1911 A.D. China. Acta Geograph Sin 2003;58:878.

10. Wang Y. Chronology of epidemic diseases in ancient China (674 B.C.–1911 A.D.). J Tianjin Uni Tradit Chin Med 2003;3:84–8.

11. Wang Y. Chronology of epidemic diseases in ancient China (674 B.C.–1911 A.D.). J Tianjin Uni Tradit Chin Med 2003;4:33–6.

12. Zhang Z. Epidemic chronology of ancient China. Fujian: Fujian Science and Technology Press; 2007.

13. Liang F. Statistics of household registration, land and tax in the ancient dynasties of China. Beijing: Zhonghua Book Company; 2008.

14. Liang Z, Zhao W. A textual research on the origin of “rooms for leprosy” in China and an investigation of its sites. Chin J Leprosy Skin Dis 1985;6:79–83.

15. Zhang L. Dr. Zhang’s medical treatment (Zhang Shi Yi tong). Beijing: China Press of Traditional Chinese Medicine; 1995.

16. Yu T. Solution to pos family diseases (Dou Ke Jin Jing Fu Ji Jie). Engraved edition of Li Songshou. Beijing: Directorate of Imperial Academy; 1876.

17. Li S. Compendium of Materia Medica. Beijing: Beijing Publishing House; 2007.

18. Sun S. Invaluable prescriptions for ready reference. Beijing: Traditional Chinese Medicine Classics Press; 1999.

19. Zhangsun W. Comment on the law in Tang dynasty. Shanghai: Shanghai Classics Publishing House; 2013.

20. Han D. A preliminary report on 102 cases of epidemic encephalitis B treated by TCM in rural areas. Shanghai J Tradit Chin Med 1958;5:8–11.

21. Wang H, Li C. A report on the therapeutic effect of traditional Chinese medicine on epidemic encephalitis B—summary of TCM treatment group in 1956. J Zhonghui Univ (Med Sci) 1958;1:1–7.

22. United TCM hospital of Quanzhou, Fujian province. A preliminary report on 83 cases of epidemic encephalitis B treated by traditional Chinese medicine. Fujian J Tradit Chin Med 1957:2:8–10.

23. Cai Y. Clinical report of ten cases of epidemic encephalitis B treated by traditional Chinese medicine. Fujian J Tradit Chin Med 1956:2:13–6.

24. Liu J, Manheimer E, Shi Y, Gluud C. Chinese herbal medicine for severe acute respiratory syndrome: a systematic review and meta-analysis. J Alter Complem Med 2004;10:1041–51.

25. WHO. SARS: clinical trials on treatment using a combination of traditional Chinese medicine and Western medicine: report of the WHO International Expert Meeting to review and analyse clinical reports on combination treatment for SARS. 8–10 October 2003. Beijing, China.

26. National Health and Health Commission. Notice on COVID-19 diagnosis and treatment plan (the sixth version). Beijing, China. 10 October 2020. Available from: http://www.nhc.gov.cn/zyywj/s7653p/202002/ 833a4a3826de6d94df329d831d7d7aa8c62.shtml.

27. National Pharmacopoeia Commission. Chinese Pharmacopoeia. Part IV. Beijing: China Medical Science Press; 2015.

28. State Administration of Traditional Chinese Medicine (SATCM). Chinese Materia Medica. Shanghai: Shanghai Scientific & Technical Publishers; 1999.

29. Lab of Systems Pharmacology. Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform. Nov 2013. Available from: http://tcmspw.com/tcmsp.php.
30. Tang S, Chen J, Geng L, Wu H, Chen C, Zhang N, et al. Research on component law of Chinese patent medicine for anti-influenza and development of new recipes for anti-influenza by unsupervised data mining methods. J Tradit Chin Med 2010;30:288—93.

31. Aghagolzadeh M, Soltanian-Zadeh H, Araabi B, Aghagolzadeh A. A hierarchical clustering based on mutual information maximization. Proc Int Conf Image Process. ICIP 2007;7:277—80. September 16—19, San Antonio, TX, USA. Institute of Electrical and Electronics Engineers. Available from: https://doi.org/10.1109/ICIP.2007.4378945.

32. Yongye AB, Waddell J, Medina-Franco JL. Molecular scaffold analysis of natural products databases in the public domain. Chem Biol Drug Des 2012;80:717—24.

33. Wang M, Li L, Yu C, Yan A, Zhao Z, Zhang G, et al. Classification of mixtures of Chinese herbal medicines based on a self-organizing map (SOM). Mol Inform 2016;35:109—15.

34. Kunimoto R, Bajorath J. Combining similarity searching and network analysis for the identification of active compounds. ACS Omega 2018;3:3768—77.

35. The R Core Team. R: a language and environment for statistical computing. Version 4.5.2., 22 Jun 2020. Copyright © 1999—2020 R Foundation for Statistical Computing. Jun 2019. Available from: https://cran.r-project.org/doc/manuals/fullrefman.pdf.

36. Mrvar A, Batagelj V. Programs for analysis and visualization of very large networks. Pajek. Version 4.5.2., 22 Jun 2020. Copyright © 1999—2019 Mrvar and Batagelj. Available from: https://pajek.casor.net.

37. NIH. U.S. national library of medicine, national center for biotechnology information, 2020. Available from: https://pubchem.ncbi.nlm.nih.gov. Bethesda, USA.

38. Yang R, Wang LQ, Yuan BC, Liu Y. The pharmacological activities of licorice. Planta Med 2015;81:1654—69.

39. Nirmala P, Selvaraj T. Anti-inflammatory and anti-bacterial activities of Glycyrrhiza glabra L. Int J Agric Technol 2011;7:815—23.

40. Wu T, Khor T, Saw C, Loh S, Chen A, Lim S, et al. Anti-inflammatory/anti-oxidative stress activities and differential regulation of Nrf2- mediated genes by non-polar fractions of tea Chrysanthemum zawadskii and licorice Glycyrrhiza uralensis. AAPS J 2011;13:1—13.

41. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. J Am Med Assoc 2003;289:2801—9.

42. Wang J, Chen X, Wang W, Zhang Y, Yang Z, Jin Y, et al. Glycyrrhizin acid as the antiviral component of Glycyrrhiza uralensis Fisch. against cowpoxvirus A16 and enterovirus 71 of hand foot and mouth disease. J Ethnopharmacol 2013;147:1—21.

43. Kwon HJ, Kim HH, Ryu YB, Kim IH, Jeong HJ, Lee SW, et al. In vitro anti-rotavirus activity of polyphenol compounds isolated from the roots of Glycyrrhiza uralensis. Bioorg Med Chem 2010;18:7668—74.

44. Shebl RI, Amin MA, Emad-Eldin A, Bin DS, Mostafa AS, Ibrahim EH, et al. Antiviral activity of liquorice powder extract against varicella zoster virus isolated from Egyptian patients. Chang Gung Med J 2012;35:231—9.

45. Luo L, Jin Y, Kim ID, Lee JK. Glycyrrhizin attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. Exp Neurobiol 2013;22:107—15.

46. Imai K, Takagi Y, Iwazaki A, Nakanishi K. Radical scavenging ability of glycyrrhizin. Free Radic Antioxidants 2013;3:40—6.

47. Fu Y, Zhou E, Wei Z, Liang D, Wang W, Wang T, et al. Glycyrrhizin inhibits the inflammatory response in mouse mammary epithelial cells and a mouse mastitis model. FEBS J 2014;281:2543—57.

48. Ni YF, Kuai JK, Lu ZF, Yang GD, Fu HY, Wang J, et al. Glycyrrhizin treatment is associated with attenuation of lipopolysaccharide-induced acute lung injury by inhibiting cyclooxygenase-2 and inducible nitric oxide synthase expression. J Surg Res 2011;165:629—35.

49. Wang CY, Kao TC, Lo WH, Yen GC. Glycyrrhizic acid and 18β-glycyrrhetinic acidmodulate lipopolysaccharide-induced inflammatory response by suppression of NF-κB through PI3K p110α and p110γ inhibitions. J Agric Food Chem 2011;59:7726—33.

50. Bhattacharjee S, Bhattacharjee A, Majumder S, Majumdar SB, Majumdar S. Glycyrrhizic acid suppresses Cox-2-mediated anti-inflammatory responses during Leishmania donovani infection. J Antimicrob Chemother 2012;67:1905—14.

51. Ishida T, Miki I, Tanahashi T, Yagi S, Kondo Y, Inoue J, et al. Effect of 18β-glycyrrhetinic acid and hydroxypropyl γ-cyclodextrin complex on indomethacin-induced small intestinal injury in mice. Eur J Pharmaco 2013;714:125—31.

52. Oztan MN, Ciftci O, Cetin A, Durak MA, Basak N, Akyuva Y. The beneficial effects of 18beta-glycyrrhetinic acid following oxidative and neuronal damage in brain tissue caused by global cerebral ischemia/reperfusion in a C57BL/6J mouse model. Neurol Sci 2014;35:1221—8.

53. Moiysy D, Avilov SV, Jacob Y, Sosa AG, Ge X, Baudin F, et al. HMGB1 protein binds to influenza virus nucleoprotein and promotes viral replication. J Virol 2012;86:9122—33.

54. Sasaki H, Takei M, Kobayashi M, Pollard RB, Suzuki F. Effect of glycyrrhizin, an active component of licorice roots, on HIV replication in cultures of peripheral blood mononuclear cells from HIV-seropositive patients. Pathobiology 2002;70:229—36.

55. Michaelis M, Geiler J, Naczk P, Sithisarn P, Ogimoto H, Altenbrandt B, et al. Glycyrrhizin inhibits highly pathogenic H5N1 influenza A virus-induced pro-inflammatory cytokine and chemokine expression in human macrophages. Med Microbiol Immunol 2010;199:291—7.

56. Kim ME, Kim HK, Kim DH, Yoon JH, Lee JS. 18β-Glycyrrhetinic acid from licorice root improves dendritic cells maturation and Th1 immune responses. Immunopharmacol Immunotoxicol 2013;35:329—35.

57. Ma C, Ma Z, Liao XL, Liu J, Fu Q, Ma S. Immunoregulatory effects of glycyrrhizic acid exerts anti-asthmatic effects via modulation of Th1/Th2 cytokines and enhancement of CD4+ CD25+ Fosp3+ regulatory T cells in ovalbumin-sensitized mice. J Ethnopharmacol 2013;148:755—62.

58. Li J, Tu Y, Tong L, Zhang W, Zheng J, Wei Q. Immunosuppressive activity on the murine immune responses of glycyrol from Glycyrrhiza uralensis via inhibition of calcineurin activity. Pharm Biol 2010;48:1177—84.

59. Lee JY, Lee JH, Park JH, Kim SY, Choi JY, Lee SH, et al. Liquiritigenin, a licorice flavonoid, helps mice resist disseminated candidiasis due to Candida albicans by Th1 immune response, whereas liqueuritinin, its glycoside form, does not. Int Immunopharmacol 2009;9:632—8.

60. Fontes LB, Dos Santos Dias D, Carvalho LS, Mesquita HL, Silva MC, Dias AT, et al. Immunomodulatory effects of licochalcone A on experimental autoimmune encephalomyelitis. J Pharm Pharmacol 2014;66:886—94.

61. Hendricks JM, Hoffman C, Pascual DW, Hardy ME. 18β-Glycyrrhetinic acid delivered orally induces isolated lymphoid follicle maturation at the intestinal mucosa and attenuates rotavirus shedding. PLoS One 2012;7:e49491.

62. Soufi H, Yassein S, Ahmed AR, Khodier MH, Kutkat MA, Nasr SM, et al. Antiviral and immune stimulant activities of glycyrrhizin against duck hepatitis virus. Afr J Tradit, Complementary Altern Med 2012;9:389—95.

63. Smirnov VS, Zarubaev VV, Anifimov PM, Shtro AA. Effect of a combination of glutamyl-tryptophan and glycyrrhetic acid on the course of acute infection caused by influenza (H3N2) virus in mice. Vopr Virusol 2012;57:23—7.

64. Li C, Lin G, Zuo Z. Pharmacological effects and pharmacokinetics properties of Radix Scutellariae and its bioactive flavones. Biopharm Drug Dispos 2011;32:427—45.

65. Yoon SB, Lee YJ, Park SK, Kim HC, Bae H, Kim HM, et al. Anti-inflammatory effects of Scutellaria baicalensis water extract on LPS-activated RAW 264.7 macrophages. J Ethnopharmacol 2009;125:286—90.

66. Chen CS, Chen NJ, Lin LW, Hsieh CC, Chen GW, Hsieh MT. Effects of Scutellariae Radix on gene expression in HEK 293 cells using cDNA microarray. J Ethnopharmacol 2006;105:346—51.
